OraSure OraQuick
This article was originally published in The Gray Sheet
Executive Summary
CDC commits to purchase of 250,000 rapid HIV-1 antibody tests for $2 mil. by Dec. 31 for 50 U.S. locations. Approved in November 2002 and CLIA-waived in January, the test will be used in CDC's HIV testing and prevention initiative. The Bethlehem, Penn. firm donated tests to eight sites for "national HIV testing day" June 27...
You may also be interested in...
OraSure’s MIRIAD results
OraQuick rapid HIV test use in point-of-care labor and delivery settings allows an average 45 minute turn-around time - more than four times faster than the 3.5 hour average needed when the same test is performed in a lab, according to CDC's Maternal Infant Rapid Intervention at Delivery study. Started in November 2001, MIRIAD tested 380 women in Chicago with 100% accuracy, finding and treating three who were HIV positive. OraQuick was approved by FDA in November 2002. CDC's previous purchase of 250,000 of the tests will be finalized in January (1"The Gray Sheet" June 30, 2003, In Brief)...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.